InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,419.20
(
0.00%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.44
(
0.37%
)
Bitcoin
64,361.72
(
0.57%
)
Post# of 18784
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DorseyE

Send PM Follow Ignore
Followers 8
Posts 2087
Boards Moderated 0
Alias Born 08/09/2003

DorseyE

Re: MR 1955 DOUBLE DIE post# 15728

Monday, 05/01/2017 11:40:50 PM

Monday, May 01, 2017 11:40:50 PM

Post# of 18784
Numerous reasons, but notice this report...
http://finance.yahoo.com/news/auris-medical-reports-key-results-120125064.html
Also read this overview...
REAL NEWS
Auris Medical's pipeline consists of drugs that are in the field of otology or the study of diseases of the ear. Keyzilen is one of Auris Medical's late stage drugs and is currently on Phase 3. Keyzilen was fast tracked by the FDA in February Keyzilen is a treatment for Acute inner ear tinnitus. If approved Keyzilen would be the first drug to gain approval to treat this disease. Right now Keyzilen is under trials of TACTT3 (A), TACTT3 (B), AMPACT 1 and AMPACT 2. Data for both TACTT 3 TRIALS is expected in quarter 1 of 2018 . While both AMPACT trials will provide data in quarter 2 of 2017. How does Keyzilen work? Well here is an explanation from Auris medical's website.
https://seekingalpha.com/article/4066693-auris-medical-company-overview
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AEZS News
More AEZS News
InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news
Only $200 per official company press release!